It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Abnormalities in GABAergic inhibitory circuits have been implicated in the aetiology of autism spectrum disorder (ASD). ASD is caused by genetic and environmental factors. Several genes have been associated with syndromic forms of ASD, including FOXG1. However, when and how dysregulation of FOXG1 can result in defects in inhibitory circuit development and ASD-like social impairments is unclear. Here, we show that increased or decreased FoxG1 expression in both excitatory and inhibitory neurons results in ASD-related circuit and social behavior deficits in our mouse models. We observe that the second postnatal week is the critical period when regulation of FoxG1 expression is required to prevent subsequent ASD-like social impairments. Transplantation of GABAergic precursor cells prior to this critical period and reduction in GABAergic tone via Gad2 mutation ameliorates and exacerbates circuit functionality and social behavioral defects, respectively. Our results provide mechanistic insight into the developmental timing of inhibitory circuit formation underlying ASD-like phenotypes in mouse models.
Cortical excitatory/inhibitory (E/I) imbalance is a feature of autism spectrum disorder (ASD). Here, the authors show that FoxG1 regulates the formation of cortical GABAergic circuits affecting social behaviour during a specific postnatal time window in mouse models of ASD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Tokyo Women’s Medical University, Department of Neurophysiology, Shinjuku, Japan (GRID:grid.410818.4) (ISNI:0000 0001 0720 6587)
2 Sleep Disorders Project, Tokyo Metropolitan Institute of Medical Science, Setagaya, Japan (GRID:grid.272456.0)
3 Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)
4 Gunma University Graduate School of Medicine, Department of Genetic and Behavioral Neuroscience, Maebashi, Japan (GRID:grid.256642.1) (ISNI:0000 0000 9269 4097)
5 NYU Neuroscience Institute, Smilow Research Center, New York University School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753); Harvard Medical School, Department of Neurobiology, Blavatnik Institute, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Stanley Center at the Broad Institute, Cambridge, USA (GRID:grid.66859.34)
6 NYU Neuroscience Institute, Smilow Research Center, New York University School of Medicine, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753)